Revance rises on Phase II data for Botox competitor
Revance Therapeutics Inc. (NASDAQ:RVNC) jumped $10.86 (41%) to $37.59 on Thursday after an interim analysis showed RT002 met the primary endpoints in the Phase II BELMONT study to treat glabellar lines. The therapy had a superior duration of response over Botox onabotulinumtoxinA from Allergan plc (NYSE:AGN).
The 268-patient study's primary endpoints were the proportion of patients with a ≥1 point improvement in Investigator Global Assessment-Facial Wrinkle Severity (IGA-FWS) score at 24 weeks and duration of response compared to Botox. Revance said all patients in each of three RT002 dose groups (20, 40 or 60 units) achieved a ≥1 point improvement in IGA-FWS score, compared to 95% for Botox and 3% for placebo. The median duration of ≥1 point improvement in IGA-FWS score was 23.6 weeks for a 40 unit dose of RT002 and 18.8 weeks with Botox (p=0.02). ...